Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Yes I get carried away sometimes with speculation (sorry, Alan), but I made a concrete prediction about mice lifespans. We shall she is my hypothesis is correct. That is science.

I do not understand those that fear death. I see death as a new beginning (NOT in the sense of personal life after death). I don’t want to die only because others would suffer.

HCN channels have been shown to undergo a hysteresis in their voltage-dependence or mode-shift in which the voltage sensitivity of gating charge movement depends on the previous state35,36,37. Moreover, since voltage-hysteresis is thought to play an important role in preventing arrhythmias35,36,37, we examined the effect of cholesterol modulation on this non-equilibrium property of the cardiac HCN isoforms. Two protocols were chosen to assess hysteresis. The addition of a short −70 mV pre-pulse prior to the activation pulses, and bidirectional ramps from 0 mV to −150 mV and back. As previously reported, HCN1 channels show a large depolarizing shift in their steady-state activation in response to a −70 mV pre-pulse (Fig. 5A). Pre-pulses induced an identical shift in the V1/2 of activation in cells that underwent cholesterol depletion by MβCD or mevastatin, as well as cholesterol enrichment by MβCD/cholesterol (Fig. 5A). Subtle effects on the slope were observed, suggesting co-operativity may be slightly affected. On the other hand HCN2 channels did not show a shift in steady-state activation following a −70 mV pre-pulse (Fig. 5B). However, depletion of membrane cholesterol strongly shifted V1/2 by  +10 mV with mevastatin treatment and +17 mV with MβCD, while the slope constants remained unchanged. Enrichment of membrane cholesterol also shifted the voltage-dependence of activation by +10 mV. The −70 mV pre-pulse induced a +10 mV shift in steady-state activation in HCN4 channels. HCN4 channels that underwent treatments of cholesterol enrichment and depletion had V1/2’s more depolarized than control, however, −70 mV pre-pulses further shifted the V1/2 of HCN4 channels in membranes enriched with cholesterol (Fig. 5C).

        Share-based compensation is recognized as an expense in the financial statements based on the grant date fair value over the requisite service period. For awards granted to employees and directors that vest based on service conditions, we use the straight-line method to allocate compensation expense to reporting periods. Beginning in the first quarter of 2017, we do not adjust stock-based compensation for estimated forfeitures and account for forfeitures when they occur.

“For another thing, Liz knew that our biotech firm, Telocyte, intends to do almost the same thing, but with a few crucial differences: we will only be using telomerase (hTERT) and we intend to pursue human trials that have FDA clearance, have full IRB agreement, and meet GMP (“Good Medical Production”) standards.”

For hypoxia experiments, cells were placed in a special hypoxia incubator infused with a gas mixture of 5% CO2 and nitrogen to obtain 3% oxygen concentration. To chemically stabilize HIFs, cells were treated with 200 μM CoCl2 (Sigma-Aldrich) or an equivalent volume of deionized water (dissolvent control) for 24 h.

        With respect to our existing and future product candidates, we may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment or to serve as an alternative to our own sales force and distribution systems. Our product revenue may be lower than if we directly marketed or sold any approved products. In addition, any revenue we receive will depend in whole or in part upon the efforts of these third parties, which may not be successful and are generally not within our control. If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize any approved products. If we are not successful in commercializing any approved products, our future product revenue will suffer and we may incur significant additional losses.

We plan to seek orphan drug designation for zilucoplan, but we may be unable to obtain such designation or to maintain the benefits associated with orphan drug status, including market exclusivity, even if that designation is granted.

Triptorelin pamoate previously was approved in 1-month (3.75 mg) and 3-month (11.25 mg) formulations.

I also have to say what a great site this is. Josh continually writes the most interesting stuff, and the commenters here do so as well.

Applications in respect of a generic medicinal product cannot be made before the expiry of the protection period. Where the reference product was granted a national marketing authorization pursuant to an application made before October 30, 2005, the protection period is either six years or 10 years, depending upon the election of the particular member state concerned. Where the reference product was granted a marketing authorization centrally, pursuant to an application made before November 20, 2005, the protection period is 10 years. For applications made after these dates, Regulation 726/2004 and amendments to Directive 2001/83/EC provide for a harmonized protection period regardless of the approval route utilized. The harmonized protection period is in total 10 years, including eight years of research data protection and two years of marketing protection. The effect is that the originator’s results can be the subject of a cross-referral application after eight years, but any resulting authorization cannot be exploited for a further two years. The rationale of this procedure is that the relevant particulars can, if the research data protection period has expired, be found on the originator’s file and used for assessment of the generic medicinal product. The 10-year protection period can be extended to 11 years where, in the first eight years post-authorization, the holder of the authorization obtains approval for a new indication assessed as offering a significant clinical benefit in comparison with existing products.